PHLPP2

Across TCGA pan-cancer cohorts, PHLPP2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PHLPP2 data layer compared with 25 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher PHLPP2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PHLPP2 expression acts as an unfavorable survival marker, although some lineages such as GBM and CCRCC show a favorable association.

GBM, LUAD, and LSCC are the cancer types where PHLPP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Median	All	0.484	0.216	<.001	31	view →
LUAD	DFS	Median	All	0.247	1.000	.038	4	view →
LSCC	DFS	Median	II,III,IV	0.201	1.000	.038	3	view →
CCRCC	DFS	Median	All	1.000	0.777	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PHLPP2–GBM (DFS)

Open the GBM breakdown →